Rebuild vs replace — synthesis beats swallowing GSH
What this is
Head-to-head evidence table: GlyNAC (precursors) vs Liposomal GSH (form).
Why it matters
GlyNAC has Tier A human RCTs restoring erythrocyte GSH over 24 weeks. Liposomal glutathione raises plasma GSH acutely but lacks equivalent longevity-trial depth.
What to do next
Load the winning stack preset in Architect and simulate interactions before purchasing.
GlyNAC has Tier A human RCTs restoring erythrocyte GSH over 24 weeks. Liposomal glutathione raises plasma GSH acutely but lacks equivalent longevity-trial depth.
Human RCT longevity markers
GlyNAC (precursors)
24-week GSH restoration (Kumar)
Liposomal GSH
Acute plasma rise; limited long-term trials
Mechanism
GlyNAC (precursors)
Endogenous synthesis — both limiting precursors
Liposomal GSH
Exogenous GSH — digestion limits intact absorption
Cost efficiency
GlyNAC (precursors)
Moderate — dual precursor
Liposomal GSH
Premium — liposomal premium pricing
GI tolerance
GlyNAC (precursors)
NAC sulfur odor; start low
Liposomal GSH
Often better tolerated
NRF2 stack fit
GlyNAC (precursors)
Designed substrate for sulforaphane
Liposomal GSH
Orthogonal — does not replace glycine need
Biomarker target
GlyNAC (precursors)
Erythrocyte GSH
Liposomal GSH
Plasma GSH (transient)
TNiC verdict
GlyNAC wins for evidence-backed stack foundation. Liposomal GSH may help short-term rescue if tolerance or compliance blocks NAC.
Choose GlyNAC (precursors) when
Choose Liposomal GSH when
Decided? Each verified pick matches the studied dose and form, and links straight to the manufacturer.
Links go to the manufacturer and may carry an affiliate token — at no extra cost to you. TNiC sells nothing and commission never moves a ranking or evidence tier. Educational information, not medical advice.